Novel agents in CLL: the importance of affordability

Emili Montserrat, MD, PhD from the University of Barcelona, Barcelona, Spain discusses the issue of drug cost in chronic lymphocytic leukemia (CLL). Prof. Montserrat points out that not all patients suffering from CLL are treated with novel agents. They have an important role, but only for a specific group of patients. Prof. Montserrat, also discusses the importance of having support from pharmaceutical companies, in order to make the cost of this therapy affordable (joining two or three agents can cost up to 300,000 Euros per year). Nevertheless, he mentions how the industry have been very good in lowering the prices in countries which are not as fortunate as the US or Europe. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

Share this video  
Similar topics